GlassScriptPhysician profile
Leonora B Bantugan
NPI 1285393181
$5,098.43
in general payments reported to CMS, 2019-2025
21 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,255 · 2023: $1,482 · 2024: $2,095 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,843.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,523.72 | 2022-2025 | Farxiga, Lokelma, Andexxa |
| Amgen INC. | $511.43 | 2024-2025 | Krystexxa, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.74 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $308.02 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $286.67 | 2022-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $260.80 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $257.53 | 2022-2023 | Velphoro, Korsuva |
| Akebia Therapeutics INC | $250.31 | 2022-2023 | Auryxia |
| Novartis Pharmaceuticals Corporation | $247.62 | 2024-2025 | |
| Glaxosmithkline, LLC. | $210.83 | 2022-2023 | Benlysta |
| Travere Therapeutics, INC. | $180.95 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $176.29 | 2024 | |
| Vifor Pharma, INC. | $128.62 | 2022-2024 | Veltassa, Korsuva |
| Dexcom, INC. | $116.99 | 2022 | |
| Genzyme Corporation | $68.22 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $43.93 | 2022 | |
| Horizon Therapeutics Plc | $37.34 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $35.85 | 2024 | Jardiance |
| Ascendis Pharma Endocrinology INC | $27.79 | 2025 | Yorvipath |
| Novo Nordisk INC | $23.40 | 2025 | Ozempic |
| Ardelyx, INC. | $20.38 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonora Bantugan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.